Pneumocystis pneumonia can complicate medical treatment of hypercortisolism even in outpatients with Cushing's disease.
ACTH Syndrome, Ectopic
/ drug therapy
Adult
Aged
Aged, 80 and over
Cushing Syndrome
/ drug therapy
Humans
Immunologic Deficiency Syndromes
/ microbiology
Male
Metyrapone
/ therapeutic use
Middle Aged
Opportunistic Infections
/ complications
Outpatients
Pneumonia, Pneumocystis
/ complications
Premedication
Retrospective Studies
Trimethoprim, Sulfamethoxazole Drug Combination
/ administration & dosage
Cushing's syndrome
Metyrapone
Métyrapone
Pneumocystosis
Pneumonie à pneumocystis
Syndrome de Cushing
Journal
Annales d'endocrinologie
ISSN: 2213-3941
Titre abrégé: Ann Endocrinol (Paris)
Pays: France
ID NLM: 0116744
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
30
09
2020
revised:
20
11
2020
accepted:
23
11
2020
pubmed:
6
12
2020
medline:
5
11
2021
entrez:
5
12
2020
Statut:
ppublish
Résumé
Several cases of Pneumocystosis pneumonia (PCP) have been reported in patients with hypercortisolism, mainly in patients with severe ectopic ACTH syndrome (EAS). We report 2 cases of PCP that did not develop until after starting treatment with metyrapone, one of which occurred in an outpatient with Cushing's disease (CD) without pulmonary symptoms before medical treatment for CD. Patient 1 presented as an outpatient with CD and severe hypercortisolism but nonetheless in good general condition. Treatment with metyrapone was started before pituitary surgery. Patient 2 had EAS due to prostate cancer. Respiratory failure in the two patients occurred 4 days and 30 days, respectively, after the start of metyrapone treatment. In both cases, chest CT showed bilateral interstitial infiltrates, and Pneumocystis jirovecii was found on bronchoalveolar lavage (BAL). A literature review was performed to identify risk factors for PCP in patients with CD: we identified 20 other cases of PCP in patients treated for hypercortisolism, including 16 patients with EAS. Ninety percent of patients had free urinary cortisol greater than 6 times the upper limit of normal (ULN). In conclusion, onset of PCP after initiation of anticortisolic therapy is not limited to patients with EAS, and may occur in CD patients with elevated cortisol levels, even if the patient remains in good general condition and has no pulmonary symptoms before treatment. In such patients, routine prophylactic treatment with trimethoprim/sulfamethoxazole (TMP/SMX) should be considered.
Identifiants
pubmed: 33278378
pii: S0003-4266(20)31302-0
doi: 10.1016/j.ando.2020.11.002
pii:
doi:
Substances chimiques
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Metyrapone
ZS9KD92H6V
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
551-560Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.